What is Sucanon®?

Clinical Trial Summary

Clinical Results

Regulatory Approvals

SUCANON®



Clinical Trial Summary:

Clinical trials on Sucanon® were performed in China.  After submission of a New Drug Application ("NDA") Sucanon® was approved by the Chinese Food and Drug Administration ("FDA").  Subsequent clinical trials were also performed on Sucanon® in Brazil.  The Brazilian study showed that equivalent clinical activity occurs in a non-Asian population.


Sucanon® clinical trials (see Clinical Results for more detailed information on trial results) were shown to reduce the problems and symptoms of Type II Diabetes:


High blood sugar:  Clinical studies have shown that Sucanon® reduces blood sugar readings by about 25% - 30% and brings high blood sugar back into the normal range (non-fasting blood sugar  is above 200 mg/dL (milligrams per deciliter) or fasting blood sugar is above 126 mg/dL).


Fatigue:  Clinical studies have shown that Sucanon® reduces fatigue.  Fatigue is a frequent symptom of Type II Diabetes or a pre-diabetic condition called Impaired Glucose Tolerance


Weight gain:  Clinical studies have shown that people who have taken Sucanon® report weight loss along with increased energy. Very often, people who are diabetic or pre-diabetic gain weight because their insulin-resistance is leading to sugar being converted into fat instead of being burned to produce energy.


Excess thirst and urination:  Clinical studies have shown that Sucanon® reduces excess thirst and excess urination. Higher-than-normal levels of blood sugar instigate thirst, which in turn leads to increased frequency of urination. 


High cholesterol and triglyceride levels:  Clinical studies have shown that Sucanon® reduces the levels of cholesterol and triglycerides.  People who are diabetic or pre-diabetic often have elevated cholesterol and triglyceride levels.  Elevated cholesterol and triglycerides significantly increase the risk of heart disease.


Side effects: Clinical studies have shown that Sucanon® showed no side effectsThis sets Sucanon® apart from many other anti-diabetic products, which can have effects on digestion, the liver, or the heart.


Toxicity: Clinical studies have shown that Sucanon® toxicity was undistinguishable from the placebo.  In addition, Sucanon® showed no carcinogenicity, mutagenicity, and teratogenicity in mice.

 


Home  |  Company  |  Diabetes  |  Sucanon  |  Investor Relations  |  Contact  |  Legal Disclaimer  |  Privacy Policy